Why “waiting to decide” quietly beats technical risk as the #1 value destroyer (and what to do about it in upcoming decade?) Pharma loves to debate technical risk : assay robustness, scale-up, stability, comparability, clinical endpoints, validation strategy. All real. But the risk that quietly outperforms all of those—year after year—is decision latency : the time between when the organization has enough information to decide and when it actually commits . Decision latency

By Moral Randeria Picture a tightrope walker over a $2.6 billion chasm—that's R&D leadership in 2026, where one misstep in financial judgment sends even the most elegant molecules crashing into oblivion.[11][4] With 41% of biopharma executives naming R&D productivity their top obsession amid costs spiraling past $2 billion per drug, the math has never been more unforgiving.[4][12] This isn't academic finance; it's survival arithmetic for the C-suite-bound. Essential Financial

By Moral Randeria, Global Pharma Strategist & Intelligence Pharmaceutical R&D executives enter 2026 confronting an unforgiving arithmetic. The industry average cost per approved therapeutic asset now exceeds 2.3 billion U.S. dollars, while the internal rate of return (IRR) for R&D investments hovers at 4.1 percent—below the cost of capital. Simultaneously, roughly 236 billion dollars in annual sales from today’s leading therapies will expire into patent cliffs by 2029. In th

From Genomic Mapping to Personalized Healthcare Introduction Precision medicine revolutionizes healthcare by customizing treatment based...